Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
AnaptysBio, Inc. filed an exhibit labeled “Execution Version Separation and Distribution Agreement” with First Tracks Biotherapeutics, Inc., dated April 20, 2026. The filing states that no agreement, oral or written, regarding the matters covered by the draft agreement has been entered into unless and until it is signed by all parties.
The exhibit outlines separation mechanics for transferring assets and liabilities, handling commingled contracts, and addressing “wrong pockets,” along with distribution actions and spinco organization documents. It also includes provisions on employee matters, shared intellectual property, indemnification and release, and access to information post-distribution.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026